{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:36:02Z","timestamp":1776695762459,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06575-9","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:09:20Z","timestamp":1751414960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Updated Japanese multicenter registry study evaluates the efficacy and safety of proton beam therapy for treating extrahepatic cholangiocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Hideya","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Iizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Waki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Fukumitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"6575_CR1","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/cncr.33476","volume":"127","author":"G Ouyang","year":"2021","unstructured":"Ouyang, G. et al. The global, regional, and national burden of the gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the global burden of disease study 2017. Cancer 127, 2238\u20132250 (2021).","journal-title":"Cancer"},{"key":"6575_CR2","unstructured":"The National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology. Biliary Tract Cancers.Version 2. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf. (2024)."},{"key":"6575_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-2004-828895","volume":"24","author":"WR Jarnagin","year":"2004","unstructured":"Jarnagin, W. R. & Shoup, M. Surgical management of cholangiocarcinoma. Semin. Liver Dis. 24, 189\u2013199 (2004).","journal-title":"Semin. Liver Dis."},{"key":"6575_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cncr.29692","volume":"122","author":"NF Esnaola","year":"2016","unstructured":"Esnaola, N. F. et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 122, 1349\u20131369 (2016).","journal-title":"Cancer"},{"key":"6575_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.semradonc.2018.06.003","volume":"28","author":"FK Keane","year":"2018","unstructured":"Keane, F. K., Zhu, A. X. & Hong, T. S. Radiotherapy for biliary tract cancers. Semin. Radiat. Oncol. 28, 342\u2013350 (2018).","journal-title":"Semin. Radiat. Oncol."},{"key":"6575_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","volume":"94","author":"N Kopek","year":"2010","unstructured":"Kopek, N. et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother. Oncol. 94, 47\u201352 (2010).","journal-title":"Radiother. Oncol."},{"key":"6575_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.adro.2016.10.008","volume":"1","author":"KA Sandler","year":"2016","unstructured":"Sandler, K. A. et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv. Radiat. Oncol. 1, 237\u2013243 (2016).","journal-title":"Adv. Radiat. Oncol."},{"key":"6575_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.21037\/jgo.2017.01.20","volume":"8","author":"R Engineer","year":"2017","unstructured":"Engineer, R. et al. High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience. J. Gastrointest. Oncol. 8, 180\u2013186 (2017).","journal-title":"J. Gastrointest. Oncol."},{"key":"6575_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/jgh.12843","volume":"30","author":"A Ohkawa","year":"2015","unstructured":"Ohkawa, A. et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. J. Gastroenterol. Hepatol. 30, 957\u2013963 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"6575_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1748-717X-9-26","volume":"9","author":"C Makita","year":"2014","unstructured":"Makita, C. et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat. Oncol. 9, 26 (2014).","journal-title":"Radiat. Oncol."},{"key":"6575_CR11","first-page":"100634","volume":"41","author":"H Yamazaki","year":"2023","unstructured":"Yamazaki, H. et al. Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients\u2019 registration database, Proton-Net. Clin. Transl. Radiat. Oncol. 41, 100634 (2023).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"6575_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u201381 (2010).","journal-title":"N. Engl. J. Med."},{"key":"6575_CR13","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958 (2019).","journal-title":"Ann. Oncol."},{"key":"6575_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca, A. et al. Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22, 690\u2013701 (2021).","journal-title":"Lancet Oncol."},{"key":"6575_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","volume":"195","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther. Onkol. 195, 93\u2013102 (2019).","journal-title":"Strahlenther. Onkol."},{"key":"6575_CR16","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1002\/cam4.1734","volume":"7","author":"D Elganainy","year":"2018","unstructured":"Elganainy, D. et al. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 7, 4880\u20134892 (2018).","journal-title":"Cancer Med."},{"key":"6575_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/COC.0000000000000646","volume":"43","author":"SP Hung","year":"2020","unstructured":"Hung, S. P. et al. Clinical outcomes of patients with unresectable cholangiocarcinoma treated with proton beam therapy. Am. J. Clin. Oncol. 43, 180\u2013186 (2020).","journal-title":"Am. J. Clin. Oncol."},{"key":"6575_CR18","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.18632\/oncotarget.27028","volume":"10","author":"G Kasuya","year":"2019","unstructured":"Kasuya, G. et al. Japan Carbon-Ion Radiation Oncology Study Group. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by the Japan carbon-ion radiation oncology study group (J-CROS). Oncotarget 10, 4369\u20134379 (2019).","journal-title":"Oncotarget"},{"key":"6575_CR19","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1002\/cncr.31334","volume":"124","author":"F Chino","year":"2018","unstructured":"Chino, F. et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer. Cancer 124, 3476\u20133489 (2018).","journal-title":"Cancer"},{"key":"6575_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/cco.2019.12.05","volume":"9","author":"S Avila","year":"2020","unstructured":"Avila, S. et al. Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma. Chin. Clin. Oncol. 9, 10 (2020).","journal-title":"Chin. Clin. Oncol."},{"key":"6575_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","volume":"34","author":"R Tao","year":"2016","unstructured":"Tao, R. et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis. J. Clin. Oncol. 34, 219\u2013226 (2016).","journal-title":"J. Clin. Oncol."},{"key":"6575_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","volume":"132","author":"TB Brunner","year":"2019","unstructured":"Brunner, T. B. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother. Oncol. 132, 42\u201347 (2019).","journal-title":"Radiother. Oncol."},{"key":"6575_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","volume":"34","author":"TS Hong","year":"2016","unstructured":"Hong, T. S. et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 34, 460\u2013468 (2016).","journal-title":"J. Clin. Oncol."},{"key":"6575_CR24","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","volume":"50","author":"JM Phelip","year":"2014","unstructured":"Phelip, J. M. et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive 9902 phase II randomised study. Eur. J. Cancer 50, 2975\u20132982 (2014).","journal-title":"Eur. J. Cancer"},{"key":"6575_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0360-3016(02)02845-6","volume":"53","author":"CH Crane","year":"2002","unstructured":"Crane, C. H. et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 969\u2013974 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"6575_CR26","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.21037\/jgo-20-245","volume":"11","author":"KR Jethwa","year":"2020","unstructured":"Jethwa, K. R. et al. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J. Gastrointest. Oncol. 11, 1408\u20131420 (2020).","journal-title":"J. Gastrointest. Oncol."},{"key":"6575_CR27","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.3390\/cancers14235864","volume":"14","author":"H Yamazaki","year":"2022","unstructured":"Yamazaki, H. et al. Particle beam therapy for intrahepatic and extrahepatic biliary duct carcinoma: A multi-institutional retrospective data analysis. Cancers 14, 5864 (2022).","journal-title":"Cancers"},{"key":"6575_CR28","first-page":"102","volume":"62","author":"SC Chen","year":"2015","unstructured":"Chen, S. C. et al. External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma. Hepatogastroenterology 62, 102\u2013107 (2015).","journal-title":"Hepatogastroenterology"},{"key":"6575_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cam4.975","volume":"6","author":"EL Pollom","year":"2017","unstructured":"Pollom, E. L. et al. Does radiotherapy still have a role in unresected biliary tract cancer?. Cancer Med. 6, 129\u2013141 (2017).","journal-title":"Cancer Med."},{"key":"6575_CR30","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1245\/s10434-017-6131-9","volume":"24","author":"A Torgeson","year":"2017","unstructured":"Torgeson, A. et al. Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: A propensity score-matched analysis. Ann. Surg. Oncol. 24, 4001\u20134008 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"6575_CR31","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"6575_CR32","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"6575_CR33","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342\u20132350 (2018).","journal-title":"N. Engl. J. Med."},{"key":"6575_CR34","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/cancers13061468","volume":"13","author":"D Marcus","year":"2021","unstructured":"Marcus, D. et al. Charged particle and conventional radiotherapy: Current implications as partner for immunotherapy. Cancers (Basel) 13, 1468 (2021).","journal-title":"Cancers (Basel)"},{"key":"6575_CR35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06575-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:09:21Z","timestamp":1751414961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06575-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6575"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06575-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6286301\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23250"}}